anmelden
Novartis Aktie
125,82
EUR
-2,16
EUR
-1,69
%
126,00
EUR
-1,38
EUR
-1,08
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 233,86 Mrd. EUR
KGV 18,30 Div. Rendite 3,38%WKN 904278
ISIN CH0012005267
Symbol NVSEF
AI Analyse
Werbung
Novartis Aktie Analyse
| 26.11.19 | Novartis Hold | Deutsche Bank AG | |
| 25.11.19 | Novartis Neutral | Credit Suisse Group | |
| 25.11.19 | Novartis Neutral | UBS AG | |
| 25.11.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 25.11.19 | Novartis buy | Jefferies & Company Inc. | |
| 18.11.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 31.10.19 | Novartis Hold | Deutsche Bank AG | |
| 30.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
|
Werbung
|
|||
| 25.10.19 | Novartis Underweight | Barclays Capital | |
| 24.10.19 | Novartis Neutral | UBS AG | |
| 24.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 23.10.19 | Novartis Neutral | Credit Suisse Group | |
| 23.10.19 | Novartis Underweight | Barclays Capital | |
| 23.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 22.10.19 | Novartis buy | Merrill Lynch & Co., Inc. | |
| 22.10.19 | Novartis buy | Jefferies & Company Inc. | |
| 22.10.19 | Novartis Underweight | Morgan Stanley | |
| 22.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 22.10.19 | Novartis Neutral | UBS AG | |
| 22.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 22.10.19 | Novartis Hold | Deutsche Bank AG | |
| 21.10.19 | Novartis Underweight | Morgan Stanley | |
| 18.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 18.10.19 | Novartis Neutral | UBS AG | |
| 17.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 07.10.19 | Novartis Neutral | UBS AG | |
| 07.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 07.10.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.10.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 17.09.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 16.09.19 | Novartis Hold | Deutsche Bank AG | |
| 13.09.19 | Novartis Conviction Buy | Goldman Sachs Group Inc. | |
| 13.09.19 | Novartis buy | Merrill Lynch & Co., Inc. | |
| 10.09.19 | Novartis Neutral | UBS AG | |
| 09.09.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 09.09.19 | Novartis Hold | Deutsche Bank AG | |
| 05.09.19 | Novartis Underweight | Barclays Capital | |
| 30.08.19 | Novartis Hold | Deutsche Bank AG | |
| 30.08.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 30.08.19 | Novartis buy | Jefferies & Company Inc. | |
| 29.08.19 | Novartis buy | Jefferies & Company Inc. | |
| 28.08.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 29.07.19 | Novartis Neutral | UBS AG | |
| 29.07.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 29.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 24.07.19 | Novartis Underweight | JP Morgan Chase & Co. | |
| 23.07.19 | Novartis Neutral | UBS AG | |
| 22.07.19 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 22.07.19 | Novartis Hold | HSBC | |
Werbung
Werbung
